rs72552300
Positions:
Variant summary
Our verdict is Pathogenic. Variant got 18 ACMG points: 18P and 0B. PVS1PM2PP5_Very_Strong
The NM_000531.6(OTC):c.67C>T(p.Arg23Ter) variant causes a stop gained change. The variant was absent in control chromosomes in GnomAD project. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Pathogenic (★★).
Frequency
Genomes: not found (cov: 23)
Consequence
OTC
NM_000531.6 stop_gained
NM_000531.6 stop_gained
Scores
2
2
1
Clinical Significance
Conservation
PhyloP100: 3.99
Genes affected
OTC (HGNC:8512): (ornithine transcarbamylase) This nuclear gene encodes a mitochondrial matrix enzyme. The encoded protein is involved in the urea cycle which functions to detoxify ammonia into urea for excretion. Mutations in this enzyme lead to ornithine transcarbamylase deficiency, which causes hyperammonemia. [provided by RefSeq, May 2022]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Pathogenic. Variant got 18 ACMG points.
PVS1
Loss of function variant, product does not undergo nonsense mediated mRNA decay. Variant located near the start codon (<100nt), not predicted to undergo nonsense mediated mRNA decay. There are 414 pathogenic variants in the truncated region.
PM2
Very rare variant in population databases, with high coverage;
PP5
Variant X-38352763-C-T is Pathogenic according to our data. Variant chrX-38352763-C-T is described in ClinVar as [Pathogenic]. Clinvar id is 97292.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | UniProt |
---|---|---|---|---|---|---|---|
OTC | NM_000531.6 | c.67C>T | p.Arg23Ter | stop_gained | 1/10 | ENST00000039007.5 | |
OTC | NM_001407092.1 | c.67C>T | p.Arg23Ter | stop_gained | 3/12 | ||
OTC | XM_017029556.2 | c.67C>T | p.Arg23Ter | stop_gained | 1/9 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|
OTC | ENST00000039007.5 | c.67C>T | p.Arg23Ter | stop_gained | 1/10 | 1 | NM_000531.6 | P1 | |
OTC | ENST00000488812.1 | n.159C>T | non_coding_transcript_exon_variant | 1/6 | 5 | ||||
OTC | ENST00000643344.1 | c.67C>T | p.Arg23Ter | stop_gained, NMD_transcript_variant | 1/11 |
Frequencies
GnomAD3 genomes Cov.: 23
GnomAD3 genomes
Cov.:
23
GnomAD4 exome Cov.: 27
GnomAD4 exome
Cov.:
27
GnomAD4 genome Cov.: 23
GnomAD4 genome
Cov.:
23
ClinVar
Significance: Pathogenic
Submissions summary: Pathogenic:4
Revision: criteria provided, multiple submitters, no conflicts
LINK: link
Submissions by phenotype
Ornithine carbamoyltransferase deficiency Pathogenic:2
Pathogenic, criteria provided, single submitter | clinical testing | ARUP Laboratories, Molecular Genetics and Genomics, ARUP Laboratories | Jul 01, 2021 | The OTC c.67C>T; p.Arg23Ter variant (rs72552300) is reported in the literature in individuals affected with ornithine transcarbamylase deficiency (Grompe 1991, Wilnai 2018). This variant is reported in ClinVar (Variation ID: 97292), and is absent from general population databases (Exome Variant Server, Genome Aggregation Database), indicating it is not a common polymorphism. This variant induces an early termination codon and is predicted to result in a truncated protein or mRNA subject to nonsense-mediated decay. Based on available information, this variant is considered to be pathogenic. References: Grompe M et al. Improved molecular diagnostics for ornithine transcarbamylase deficiency. Am J Hum Genet. 1991 Feb;48(2):212-22. Wilnai Y et al. Prenatal treatment of ornithine transcarbamylase deficiency. Mol Genet Metab. 2018 Mar;123(3):297-300. - |
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Aug 03, 2022 | For these reasons, this variant has been classified as Pathogenic. ClinVar contains an entry for this variant (Variation ID: 97292). This premature translational stop signal has been observed in individual(s) with ornithine transcarbamylase deficiency (PMID: 1671317, 18604903). This variant is not present in population databases (gnomAD no frequency). This sequence change creates a premature translational stop signal (p.Arg23*) in the OTC gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in OTC are known to be pathogenic (PMID: 10946359, 16786505). - |
not provided Pathogenic:2
Pathogenic, no assertion criteria provided | literature only | GenMed Metabolism Lab | - | - - |
Pathogenic, criteria provided, single submitter | clinical testing | GeneDx | Mar 31, 2023 | Nonsense variant predicted to result in protein truncation or nonsense mediated decay in a gene for which loss-of-function is a known mechanism of disease; Not observed in large population cohorts (gnomAD); This variant is associated with the following publications: (PMID: 10946359, 24485820, 1671317, 18604903, 29396029, 9286441, 11793468, 11117428, 25433810, 19138872, 33489762, 33309754, 33272297, 32778825) - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
BayesDel_addAF
Pathogenic
D
BayesDel_noAF
Pathogenic
CADD
Pathogenic
DANN
Uncertain
FATHMM_MKL
Uncertain
D
MutationTaster
Benign
A
Vest4
GERP RS
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at